Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth 2021-2026

  • receipt Report ID : 241166
  • calendar_today Published On: Apr, 2021
  • file_copy Pages: 167
  • list Pharmaceuticals and Healthcare

According to this latest study, the 2021 growth of Chemotherapy Induced Peripheral Neuropathy Treatment will have significant change from previous year. By the most conservative estimates of global Chemotherapy Induced Peripheral Neuropathy Treatment market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1538.4 million in 2020. Over the next five years the Chemotherapy Induced Peripheral Neuropathy Treatment market will register a 6.6% CAGR in terms of revenue, the global market size will reach US$ 1989.5 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Peripheral Neuropathy Treatment market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.

Platinum Agents

Taxanes

Vinca Alkaloids

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Solasia Pharma K.K.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption 2016-2026

2.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption CAGR by Region

2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

2.2.1 Calcium Channel α2-delta Ligands

2.2.2 Antidepressants

2.2.3 Opioids

2.2.4 Others

2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2016-2021)

2.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Type (2016-2021)

2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

2.4.1 Platinum Agents

2.4.2 Taxanes

2.4.3 Vinca Alkaloids

2.4.4 Others

2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

2.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Market Share by Application (2016-2021)

2.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Application (2016-2021)

2.5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Application (2016-2021)

3 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company

3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company

3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2019-2021)

3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2019-2021)

3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company

3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2019-2021)

3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2019-2021)

3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Company

3.4 Global Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Location Distribution

3.4.2 Players Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Chemotherapy Induced Peripheral Neuropathy Treatment by Region

4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Region

4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region

4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region

4.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth

4.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth

4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth

4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth

5 Americas

5.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country

5.1.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021)

5.1.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021)

5.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

5.3 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region

6.1.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2016-2021)

6.1.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021)

6.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

6.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Country

7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021)

7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021)

7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Country

8.1.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021)

8.1.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021)

8.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

8.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Country

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors

10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customer

11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast

11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Region

11.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Regions (2021-2026)

11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Regions (2021-2026)

11.2 Americas Forecast by Country

11.3 APAC Forecast by Region

11.4 Europe Forecast by Country

11.5 Middle East & Africa Forecast by Country

11.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Type

11.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Application

12 Key Players Analysis

12.1 Aptinyx Inc

12.1.1 Aptinyx Inc Company Information

12.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.1.4 Aptinyx Inc Main Business Overview

12.1.5 Aptinyx Inc Latest Developments

12.2 Asahi Kasei Pharma Corp

12.2.1 Asahi Kasei Pharma Corp Company Information

12.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.2.4 Asahi Kasei Pharma Corp Main Business Overview

12.2.5 Asahi Kasei Pharma Corp Latest Developments

12.3 Regenacy Pharmaceuticals

12.3.1 Regenacy Pharmaceuticals Company Information

12.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.3.4 Regenacy Pharmaceuticals Main Business Overview

12.3.5 Regenacy Pharmaceuticals Latest Developments

12.4 MAKScientific LLC

12.4.1 MAKScientific LLC Company Information

12.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.4.4 MAKScientific LLC Main Business Overview

12.4.5 MAKScientific LLC Latest Developments

12.5 Metys Pharmaceuticals AG

12.5.1 Metys Pharmaceuticals AG Company Information

12.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.5.4 Metys Pharmaceuticals AG Main Business Overview

12.5.5 Metys Pharmaceuticals AG Latest Developments

12.6 Nemus Bioscience Inc

12.6.1 Nemus Bioscience Inc Company Information

12.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.6.4 Nemus Bioscience Inc Main Business Overview

12.6.5 Nemus Bioscience Inc Latest Developments

12.7 PledPharma

12.7.1 PledPharma Company Information

12.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.7.4 PledPharma Main Business Overview

12.7.5 PledPharma Latest Developments

12.8 Sova Pharmaceuticals Inc

12.8.1 Sova Pharmaceuticals Inc Company Information

12.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.8.4 Sova Pharmaceuticals Inc Main Business Overview

12.8.5 Sova Pharmaceuticals Inc Latest Developments

12.9 DermaXon LLC

12.9.1 DermaXon LLC Company Information

12.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.9.4 DermaXon LLC Main Business Overview

12.9.5 DermaXon LLC Latest Developments

12.10 Kineta Inc

12.10.1 Kineta Inc Company Information

12.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.10.4 Kineta Inc Main Business Overview

12.10.5 Kineta Inc Latest Developments

12.11 Krenitsky Pharmaceuticals Inc

12.11.1 Krenitsky Pharmaceuticals Inc Company Information

12.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.11.4 Krenitsky Pharmaceuticals Inc Main Business Overview

12.11.5 Krenitsky Pharmaceuticals Inc Latest Developments

12.12 PeriphaGen

12.12.1 PeriphaGen Company Information

12.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.12.4 PeriphaGen Main Business Overview

12.12.5 PeriphaGen Latest Developments

12.13 Apexian Pharma

12.13.1 Apexian Pharma Company Information

12.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.13.4 Apexian Pharma Main Business Overview

12.13.5 Apexian Pharma Latest Developments

12.14 WinSanTor

12.14.1 WinSanTor Company Information

12.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.14.4 WinSanTor Main Business Overview

12.14.5 WinSanTor Latest Developments

12.15 Solasia Pharma K.K.

12.15.1 Solasia Pharma K.K. Company Information

12.15.2 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

12.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2019-2021)

12.15.4 Solasia Pharma K.K. Main Business Overview

12.15.5 Solasia Pharma K.K. Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Chemotherapy Induced Peripheral Neuropathy Treatment Consumption CAGR by Region (2020-2026) & ($ Millions)

Table 2. Major Players of Calcium Channel α2-delta Ligands

Table 3. Major Players of Antidepressants

Table 4. Major Players of Opioids

Table 5. Major Players of Others

Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)

Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & ($ million)

Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)

Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Type (2016-2021)

Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)

Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Value by Application (2016-2021)

Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)

Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Application (2016-2021)

Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2019-2021) & (K Units)

Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2019-2021)

Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2019-2021) ($ Millions)

Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2019-2021)

Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Company (2019-2021)

Table 21. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Producing Area Distribution and Sales Area

Table 22. Players Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered

Table 23. Chemotherapy Induced Peripheral Neuropathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2016-2021) (K Units)

Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)

Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021) & ($ Millions)

Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)

Table 30. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)

Table 31. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)

Table 32. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & ($ Millions)

Table 33. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)

Table 34. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)

Table 35. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

Table 36. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)

Table 37. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Table 38. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2016-2021) & (K Units)

Table 39. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)

Table 40. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021) & ($ Millions)

Table 41. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)

Table 42. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)

Table 43. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

Table 44. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)

Table 45. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Table 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)

Table 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)

Table 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & ($ Millions)

Table 49. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)

Table 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)

Table 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)

Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Table 54. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2016-2021) & (K Units)

Table 55. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2016-2021)

Table 56. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & ($ Millions)

Table 57. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2021)

Table 58. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)

Table 59. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)

Table 60. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)

Table 61. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Table 62. Key and Potential Regions of Chemotherapy Induced Peripheral Neuropathy Treatment

Table 63. Key Application and Potential Industries of Chemotherapy Induced Peripheral Neuropathy Treatment

Table 64. Key Challenges of Chemotherapy Induced Peripheral Neuropathy Treatment

Table 65. Key Trends of Chemotherapy Induced Peripheral Neuropathy Treatment

Table 66. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List

Table 67. Chemotherapy Induced Peripheral Neuropathy Treatment Customer List

Table 68. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2021-2026) & (K Units)

Table 69. Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Forecast by Region

Table 70. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2021-2026) & ($ millions)

Table 71. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Region (2021-2026)

Table 72. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2021-2026) & (K Units)

Table 73. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Country (2021-2026) & ($ millions)

Table 74. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2021-2026) & (K Units)

Table 75. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2021-2026) & ($ millions)

Table 76. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2021-2026) & (K Units)

Table 77. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Country (2021-2026) & ($ millions)

Table 78. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2021-2026) & (K Units)

Table 79. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Country (2021-2026) & ($ millions)

Table 80. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2021-2026) & (K Units)

Table 81. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2021-2026)

Table 82. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2021-2026) & ($ Millions)

Table 83. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Type (2021-2026)

Table 84. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2021-2026) & (K Units)

Table 85. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Application (2021-2026)

Table 86. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2021-2026) & ($ Millions)

Table 87. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Application (2021-2026)

Table 88. Aptinyx Inc Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 89. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 90. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 91. Aptinyx Inc Main Business

Table 92. Aptinyx Inc Latest Developments

Table 93. Asahi Kasei Pharma Corp Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 94. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 95. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 96. Asahi Kasei Pharma Corp Main Business

Table 97. Asahi Kasei Pharma Corp Latest Developments

Table 98. Regenacy Pharmaceuticals Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 99. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 100. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 101. Regenacy Pharmaceuticals Main Business

Table 102. Regenacy Pharmaceuticals Latest Developments

Table 103. MAKScientific LLC Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 104. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 105. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 106. MAKScientific LLC Main Business

Table 107. MAKScientific LLC Latest Developments

Table 108. Metys Pharmaceuticals AG Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 109. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 110. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 111. Metys Pharmaceuticals AG Main Business

Table 112. Metys Pharmaceuticals AG Latest Developments

Table 113. Nemus Bioscience Inc Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 114. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 115. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 116. Nemus Bioscience Inc Main Business

Table 117. Nemus Bioscience Inc Latest Developments

Table 118. PledPharma Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 119. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 120. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 121. PledPharma Main Business

Table 122. PledPharma Latest Developments

Table 123. Sova Pharmaceuticals Inc Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 124. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 125. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 126. Sova Pharmaceuticals Inc Main Business

Table 127. Sova Pharmaceuticals Inc Latest Developments

Table 128. DermaXon LLC Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 129. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 130. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 131. DermaXon LLC Main Business

Table 132. DermaXon LLC Latest Developments

Table 133. Kineta Inc Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 134. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 135. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 136. Kineta Inc Main Business

Table 137. Kineta Inc Latest Developments

Table 138. Krenitsky Pharmaceuticals Inc Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 139. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 140. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 141. Krenitsky Pharmaceuticals Inc Main Business

Table 142. Krenitsky Pharmaceuticals Inc Latest Developments

Table 143. PeriphaGen Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 144. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 145. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 146. PeriphaGen Main Business

Table 147. PeriphaGen Latest Developments

Table 148. Apexian Pharma Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 149. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 150. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 151. Apexian Pharma Main Business

Table 152. Apexian Pharma Latest Developments

Table 153. WinSanTor Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 154. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 155. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 156. WinSanTor Main Business

Table 157. WinSanTor Latest Developments

Table 158. Solasia Pharma K.K. Basic Information, Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base, Sales Area and Its Competitors

Table 159. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered

Table 160. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 161. Solasia Pharma K.K. Main Business

Table 162. Solasia Pharma K.K. Latest Developments

List of Figures

Figure 1. Picture of Chemotherapy Induced Peripheral Neuropathy Treatment

Figure 2. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate 2016-2026 (K Units)

Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2016-2026 ($ Millions)

Figure 8. Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021 & 2026) & ($ millions)

Figure 9. Product Picture of Calcium Channel α2-delta Ligands

Figure 10. Product Picture of Antidepressants

Figure 11. Product Picture of Opioids

Figure 12. Product Picture of Others

Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020

Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)

Figure 15. Chemotherapy Induced Peripheral Neuropathy Treatment Consumed in Platinum Agents

Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Platinum Agents (2016-2021) & (K Units)

Figure 17. Chemotherapy Induced Peripheral Neuropathy Treatment Consumed in Taxanes

Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Taxanes (2016-2021) & (K Units)

Figure 19. Chemotherapy Induced Peripheral Neuropathy Treatment Consumed in Vinca Alkaloids

Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Vinca Alkaloids (2016-2021) & (K Units)

Figure 21. Chemotherapy Induced Peripheral Neuropathy Treatment Consumed in Others

Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Others (2016-2021) & (K Units)

Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)

Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application in 2020

Figure 25. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market by Company in 2020 ($ Million)

Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company in 2020

Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions (2016-2021)

Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2020

Figure 29. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2021 (K Units)

Figure 30. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2016-2021 ($ Millions)

Figure 31. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2021 (K Units)

Figure 32. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2016-2021 ($ Millions)

Figure 33. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2021 (K Units)

Figure 34. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2016-2021 ($ Millions)

Figure 35. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2016-2021 (K Units)

Figure 36. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2016-2021 ($ Millions)

Figure 37. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 38. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2020

Figure 39. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020

Figure 40. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020

Figure 41. United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 42. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 43. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 44. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 45. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2020

Figure 46. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions in 2020

Figure 47. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020

Figure 48. APAC Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020

Figure 49. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 50. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 51. Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 52. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 53. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 54. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 55. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 56. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2020

Figure 57. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020

Figure 58. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020

Figure 59. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 60. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 61. UK Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 62. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 63. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 64. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2020

Figure 65. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2020

Figure 66. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020

Figure 67. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020

Figure 68. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 69. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 70. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 71. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 72. GCC Country Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth 2016-2021 ($ Millions)

Figure 73. Channels of Distribution

Figure 74. Distributors Profiles

Please fill the form below, to recieve the report sample


+1